Blackstone Credit & Insurance Leads $1.3 Billion Financing to Support Combination of Paratek Pharmaceuticals and Radius Health

NEW YORK - March 18, 2026 - Blackstone Credit & Insurance ("BXCI") today announced that it is leading a $1.3 billion financing in support of the combination of Paratek Pharmaceuticals ("Paratek") and Radius Health ("Radius") that creates a scaled, multi-asset specialty pharmaceutical company.

As announced today, the newly combined Company is a specialty pharmaceutical platform with a portfolio of diverse, innovative medicines well-positioned for long-term growth. Paratek is expected to generate nearly $1 billion in annual revenue in 2026, reflecting the scale and breadth of the platform. The transaction brings together two complementary organizations backed by B-FLEXION Life Sciences, and further advances Paratek's growth strategy of building a pharmaceutical platform in high-need, targeted therapeutic areas.

"We are pleased to support B-FLEXION and management in the creation of a scaled specialty pharmaceutical platform," said Jonathan Brayman, Managing Director, BXCI. "This transaction reflects our ability to provide large-scale capital solutions to life sciences companies."

"We are proud to partner with Blackstone on this next phase of growth for Paratek, as it is a transformative transaction for both the organization and the broader platform," said Peter Agnes, Operating Partner at B-Flexion Life Sciences. "This also represents an exciting next step in Paratek's ability to serve patients and communities across a growing number of therapeutic areas."

About Blackstone Credit & Insurance
Blackstone Credit & Insurance is one of the world's leading credit investors. Our investments span the credit markets, including private investment grade, asset-based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.

About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a specialty pharmaceutical company with a portfolio of differentiated medicines serving patients across multiple therapeutic areas. The company integrates and advances commercial-stage assets through disciplined commercial execution, lifecycle management, and clinical development initiatives designed to expand and strengthen its portfolio. Paratek's products include NUZYRA® (omadacycline), XHANCE® (fluticasone propionate), and TYMLOS® (abaloparatide). Paratek is privately held by B-FLEXION Life Sciences. For more information, visit https://www.paratekpharma.com/ or follow us on LinkedIn and X.

About B-FLEXION Life Sciences
B-FLEXION Life Sciences is an investment manager and part of the wider B-FLEXION group, the private, entrepreneurial investment firm that has offices across Europe and the United States and which seeds, acquires and builds investment partnerships across a number of focused fields. Through B-FLEXION Life Sciences it also makes principal investments in operating businesses across biotech, therapeutics, diagnostics, physician practice management, and more. It is an active owner, applying the experience and skills of its investment and operations team to work closely with management at its portfolio companies with the shared goals of bringing safe and effective treatments to market while also moving towards and through key value inflection points. www.bflexion.com

Contact
David Vitek
(212) 583-5291
[email protected]